new hope for diabetic heart

Preclinical study published in journal Cardiovascular Diabetology revealed that lipoxin A4 (LXA4) moleculeknown for its ability to deactivate chronic inflammation, can become Innovative treatment of cardiovascular diseases caused by diabetes. Conditions such as atherosclerosis, heart attacks and heart failure are the leading causes of death in people with diabetes, according to researchers.

LXA4 could be a breakthrough treatment for cardiovascular disease caused by diabetes

Research team led by Chengxue Helena Qin from the Monash Institute of Pharmaceutical Sciences (MIPS)emphasized that chronic inflammation is a determining factor in the progressive heart damage of patients with diabetes. Qin explained that in preclinical animal models, it was found that LXA4 can significantly reduce inflammation and scarring in heart tissue, improving its functionality. In addition, he emphasized that recent advances in optimizing this molecule for pharmacological use increase its therapeutic potential.

.

Personalized therapy.

Currently, methods of treating inflammation in patients with diabetes do not differ from methods of treating other types of cardiovascular diseases. Philip Kantharidis, study co-author and fellow at Monash Diabetes Unit. The specialist said the findings provide an opportunity to develop more specific and effective treatments to complement conventional medications for controlling blood sugar levels.

Currently, methods of treating inflammation in patients with diabetes are not differentiated from methods of treating other types of cardiovascular diseases.

On the other hand, Ting Fu, a doctoral student and first author of the study, detailed how LXA4 Benefits Diabetic Heart Immune System. Fu noted that This molecule stimulates the activity of reparative macrophages, key cells in the repair of damaged cardiac tissue.

. These macrophages will not only help reduce scarring caused by chronic inflammation, but will also improve overall heart function in the models analyzed.

LXA4

While the results are promising, the researchers noted that work remains to be done before this therapy can be used clinically. Work is currently underway to develop a more stable version of the LXA4 molecule, which could be used as the basis for a drug. Besides, The application of these findings is being explored in other inflammatory diseases, and additional pharmacological options are being explored for the treatment of various cardiopulmonary diseases..

This scientific breakthrough offers new hope for people with diabetes, who face an increased risk of heart disease.

The study, which involved MIPS, Monash University’s Department of Diabetes and University College Dublin, highlights the impact of interdisciplinary research in solving complex health problems. According to researchers, lLXA4-based therapy could transform the treatment of diabetic heart disease, benefiting thousands of patients worldwide.

Nevertheless, This scientific breakthrough offers new hope for people with diabetes, who face an increased risk of heart disease.. Although more research is needed to translate these findings into clinical practice, the researchers believe LXA4-based therapy could be a turning point in the treatment of diabetic heart disease.

---

You may also be interested…